Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban exposure evaluation in anticoagulant-naive NVAF patients with high creatinine clearance
2016-001795-30Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of edoxaban in nonvalvular atrial fibrillation (NVAF) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Average concentration at steady state (Cav), Minimum concentration in plasma (Cmin) and 1 more. Started Sep 2016; status: completed.
02
Drugs
edoxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on 2016-001795-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001795-30.